OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Foldi on the Evolving Treatment Landscape of ADCs in HER2+ Breast Cancer

June 4th 2024

Julia Foldi, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment paradigm for metastatic HER2-positive breast cancer.

Dr Facon on the Efficacy of Isa-VRd in Newly Diagnosed Multiple Myeloma

June 3rd 2024

Thierry Facon, MD, discusses findings from the phase 3 IMROZ trial investigating Isa-VRd in patients with newly diagnosed multiple myeloma.

Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 3rd 2024

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Dr Aranha on Data Informing HIPEC Use in Peritoneal Carcinomatosis of GI Malignancies

June 3rd 2024

Olivia Aranha, MD, PhD, discusses data supporting the use of HIPEC for patients with peritoneal carcinomatosis in gastrointestinal malignancies.

Dr Iglesia on the Potential Role for Disease Etiology in Frontline HCC Treatment Selection

June 3rd 2024

Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.

Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC

June 2nd 2024

Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

June 2nd 2024

Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

June 1st 2024

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC

June 1st 2024

Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

May 31st 2024

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

May 31st 2024

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.

Dr Lovly on the Investigation of BDTX-1535 in NSCLC

May 31st 2024

Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal Cancer

May 30th 2024

Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Dr Porter on the Future of CAR T-Cell Therapy in Relapsed/Refractory CLL

May 30th 2024

David L. Porter, MD, discusses the future of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr Yap on the Continued Investigation of Saruparib in Advanced Solid Tumors

May 30th 2024

Timothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.

Dr Gordon on the FDA Approval of Liso-Cel in Relapsed/Refractory MCL

May 30th 2024

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

Dr Carraway on the Importance of NGS in Relapsed/Refractory AML

May 29th 2024

Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.

Dr Braun on the Evolution of Immunotherapy Combinations in RCC

May 29th 2024

David A. Braun, MD, PhD, discusses considerations with immunotherapy-based regimens in patients with renal cell carcinoma.

Dr Foldi on the Impact of ILD in HER2+ Breast Cancer Treatment

May 29th 2024

Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.

Dr Narayan on the Utility of Nadofaragene Firadenovec in NMIBC and Beyond

May 29th 2024

Vikram M. Narayan, MD, discusses the utility of nadofaragene firadenovec in patients with non–muscle-invasive bladder cancer and beyond.